APOE and early-onset autosomal dominant Alzheimer disease: APOE ε4 is commonly and increasingly used for personalized medicine, as a direct-to-consumer test, and is also now a required part of risk counseling for amyloid-beta monoclonal antibodies for Alzheimer's disease [23].